Keyword: Nektar Therapeutics
The 27-0 vote against approval followed questioning of Nektar’s decision to run one pivotal trial and the extent to which it assessed the abuse risk.
The phase 1/2 results show the efficacy seen at 12 months has persisted, providing early evidence of durable responses.
7. Thomas Lynch, Bristol-Myers Squibb
Two months after Nektar Therapeutics handed off its lead pain drug to a new subsidiary, the FDA is postponing an advisory panel meeting for that drug.
Nektar Therapeutics has posted updated data on its NKTR-214-Opdivo cocktail in first-line melanoma that features four more complete responses.
Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.
Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help longer term
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.
Dermavant hires Zavodnick as CEO; Bayer VP to lead Matoke Pharma; and Genentech I-O leader Wei Lin will head up Nektar's oncology work.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.